DeepSon Bio at Korean Society of Brain Neuromodulation Therapy
Professor Kim Jae-ho presented positive findings from an exploratory clinical trial using Deepson Bio’s NEUCLARE therapeutic ultrasound device to...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy manufacturing compliance Oncology Trials Opinion Parkinson's Disease Patient Stratification Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Professor Kim Jae-ho presented positive findings from an exploratory clinical trial using Deepson Bio’s NEUCLARE therapeutic ultrasound device to...
In this interview, we sat down with James Burt, CEO of Pharmanovia, to reflect on industry trends from 2024...
InnoCare Pharma received approval from China’s CDE to begin a Phase III trial of its BCL2 inhibitor, ICP-248 (Mesutoclax),...
The FDA approved GSK’s PENMENVY, a combination vaccine against five serogroups of meningococcal disease (A, B, C, W, and...
Scientists in Cambridge developed a new prostate cancer test designed to revolutionize screening, diagnosis, and personalized treatment. The test...
Innate Pharma received Breakthrough Therapy Designation from the FDA for lacutamab, its anti-KIR3DL2 antibody, for treating relapsed or refractory...
A single-center study at the University Medical Center of Astana, Kazakhstan, demonstrated the effectiveness of the Aeson® total artificial...
Regeneron and Sanofi announced that the FDA accepted for Priority Review their supplemental Biologics License Application for Dupixent (dupilumab)...
In this discussion with Kathleen Mandziuk, Vice President of eClinical Development & Delivery at ICON, we explore the dynamic...
Richard Young, Chief Strategy Officer at CluePoints, shares insights on AI and risk-based quality management (RBQM) in clinical trials....